Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
暂无分享,去创建一个
M. Colombo | S. Canevari | Z. Eshhar | G. Parmiani | G. Casorati | M. Figini | C. Melani | D. Nicosia | E. Luison | V. Ramakrishna
[1] S. Canevari,et al. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. , 1998, Cancer research.
[2] S. Gillies,et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. , 1997, Cancer research.
[3] V. Brusic,et al. Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA‐restricted cytotoxic T cells , 1997, International journal of cancer.
[4] A. Eggermont,et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. , 1995, Journal of the National Cancer Institute.
[5] G. Maass,et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[6] E. Atkinson,et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[7] J. Xiang,et al. Single‐chain antibody variable region‐targeted interleukin‐2 stimulates T cell killing of human colorectal carcinoma cells , 1994, Immunology and cell biology.
[8] V. Zurawski,et al. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. , 1994, Cancer research.
[9] M. Colombo,et al. Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. , 1994, Natural immunity.
[10] T. Blankenstein,et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[11] T. Clackson,et al. Making antibody fragments using phage display libraries , 1991, Nature.
[12] S. Canevari,et al. Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor‐associated antigen: Analysis of cell binding and internalization , 1991, International journal of cancer.
[13] H. P. Fell,et al. Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2. , 1991, Journal of immunology.
[14] E. Gilboa,et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.
[15] W. Urba,et al. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] B. Vogelstein,et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.
[17] K. Karjalainen,et al. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules , 1989, Nature.
[18] S. Ménard,et al. Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity , 1987, International journal of cancer.
[19] J. da Silva,et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.
[20] J. Marchalonis. An enzymic method for the trace iodination of immunoglobulins and other proteins. , 1969, The Biochemical journal.
[21] J. Becker,et al. Immunocytokines: a new approach to immunotherapy of melanoma , 1997, Melanoma research.
[22] F. Farzaneh,et al. Ovarian tumour antigens as potential targets for immune gene therapy. , 1995, Gene therapy.
[23] E. Seregni,et al. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. , 1995, European journal of cancer.
[24] S. Canevari,et al. Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[25] G. Bastert,et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. , 1991, European journal of cancer.
[26] S. Stewart,et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered monoclonal antibodies , 1988 .